Wall Street analyst estimates for RadNet, Inc. (RDNT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures.
Analyst Consensus
| Strong Buy | 1 |
| Buy | 8 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.91 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $0.21 | ||
| 2026-08-09 | $0.29 | $0.20 | +44.0% |
| 2026-05-11 | $-0.28 | $-0.14 | -100.0% |
| 2026-03-02 | $0.23 | $0.19 | +21.1% |
| 2025-11-10 | $0.20 | $0.22 | -10.3% |
| 2025-08-11 | $0.31 | $0.17 | +82.4% |
| 2025-05-11 | $-0.50 | $-0.17 | -194.1% |
| 2025-02-27 | $0.07 | $0.15 | -51.6% |
Valuation Ratios
| Price / Book | 4.96 |
| EV / EBITDA | 20.77 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $884.5M | $922.2M | $975.1M | $1.15B | $1.07B | $1.32B | $1.43B | $1.62B | $1.83B | $2.04B |
| Cost of Revenue | $775.8M | $802.4M | $867.5M | $999.7M | $965.9M | $1.12B | $1.26B | $1.40B | $1.58B | $1.95B |
| Gross Profit | $108.7M | $119.8M | $107.6M | $154.5M | $105.9M | $191.8M | $165.7M | $221.4M | $249.1M | $90.8M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $2.9M | $1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | $66.6M | $66.8M | $72.9M | $84.6M | $70.3M | $109.2M | $119.4M | $122.7M | $144.5M | 0 |
| Operating Income | $38.5M | $50.0M | $30.9M | $69.9M | $35.7M | $82.6M | $46.4M | $98.7M | $104.6M | $90.8M |
| EBITDA | $108.7M | $119.8M | $107.6M | $225.2M | $199.7M | $278.4M | $278.5M | $292.8M | $262.5M | $253.9M |
| Interest Expense | $43.5M | $40.6M | $43.5M | $48.0M | $45.9M | $48.8M | $50.8M | $64.5M | $79.8M | $69.9M |
| Pre-tax Income | $12.4M | $26.4M | $38.5M | $29.7M | -$854,000 | $58.9M | $43.0M | $38.8M | $44.9M | $31.9M |
| Income Tax | $4.4M | $24.3M | $394,000 | $6.2M | $895,000 | $14.6M | $9.4M | $8.5M | $6.0M | $14.9M |
| Net Income | $7.2M | $53,000 | $32.2M | $14.8M | -$14.8M | $24.7M | $10.7M | $3.0M | $2.8M | -$18.7M |
| EPS | $0.16 | $0.00 | $0.67 | $0.47 | $-0.29 | $0.47 | $0.19 | $0.05 | $0.04 | $-0.25 |
| EPS (Diluted) | $0.15 | $0.00 | $0.66 | $0.47 | $-0.29 | $0.46 | $0.17 | $0.05 | $0.04 | $-0.25 |
| Shares Outstanding (Diluted) | $46.7M | $47.4M | $48.7M | $50.2M | $50.9M | $53.4M | $57.3M | $64.7M | $74.8M | $75.2M |
Price
| Price | $70.57 |
| Market Cap | $5.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BLCO · BRKR · BTSG · CHE · IRTC · KRYS · MMSI
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of RDNT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks